Olga A. Chernova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olga A. Chernova has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Vladislav M. Chernov
Kazan Institute of Biochemistry and Biophysics, Kazan Scientific Centre of the Russian Academy of Sciences, Kazan, Russia
42 shared publications - Oleg V. Gorshkov
Kazan Institute of Biochemistry and Biophysics, FRC Kazan Scientific Center of RAS, Lobachevsky Str., 2/31, 420111 Kazan, Russia
15 shared publications Alexey A. Mouzykantov
A Kazan Institute of Biochemistry and Biophysics , FRC Kazan Scientific Center of RAS , Kazan , Russian Federation
10 shared publications- Maxim Victorovich Trushin
Kazan Federal University Kazan Russia
10 shared publications E. S. Medvedeva
Kazan Institute of Biochemistry and Biophysics, Kazan Scientific Center, RAS, Kazan, Russia
7 shared publicationsN. B. Baranova
Kazan Institute of Biochemistry and Biophysics, Kazan Scientific Center, RAS, Kazan, Russia
7 shared publications
Latest Publications
- Open Access
Effects of Mycoplasmas on the Host Cell Signaling Pathways
Mycoplasmas are the smallest free-living organisms. Reduced sizes of their genomes put constraints on the ability of these bacteria to live autonomously and make them highly dependent on the nutrients produced by host cells. Importantly, at the organism level, mycoplasmal infections may cause pathological changes to the host, including cancer and severe immunological reactions. At the molecular level, mycoplasmas often activate the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) inflammatory response and concomitantly inhibit the p53-mediated response, which normally triggers the cell cycle and apoptosis. Thus, mycoplasmal infections may be considered as cancer-associated factors. At the same time, mycoplasmas through their membrane lipoproteins (LAMPs) along with lipoprotein derivatives (lipopeptide MALP-2, macrophage-activating lipopeptide-2) are able to modulate anti-inflammatory responses via nuclear translocation and activation of Nrf2 (the nuclear factor-E2-related anti-inflammatory transcription factor 2). Thus, interactions between mycoplasmas and host cells are multifaceted and depend on the cellular context. In this review, we summarize the current information on the role of mycoplasmas in affecting the host’s intracellular signaling mediated by the interactions between transcriptional factors p53, Nrf2, and NF-κB. A better understanding of the mechanisms underlying pathologic processes associated with reprogramming eukaryotic cells that arise during the mycoplasma-host cell interaction should facilitate the development of new therapeutic approaches to treat oncogenic and inflammatory processes.
Open AccessEffects of Mycoplasmas on the Host Cell Signaling Pathways
Mycoplasmas are the smallest free-living organisms. Reduced sizes of their genomes put constraints on the ability of these bacteria to live autonomously and make them highly dependent on the nutrients produced by host cells. Importantly, at the organism level, mycoplasmal infections may cause pathological changes to the host, including cancer and severe immunological reactions. At the molecular level, mycoplasmas often activate the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) inflammatory response and concomitantly inhibit the p53-mediated response, which normally triggers the cell cycle and apoptosis. Thus, mycoplasmal infections may be considered as cancer-associated factors. At the same time, mycoplasmas through their membrane lipoproteins (LAMPs) along with lipoprotein derivatives (lipopeptide MALP-2, macrophage-activating lipopeptide-2) are able to modulate anti-inflammatory responses via nuclear translocation and activation of Nrf2 (the nuclear factor-E2-related anti-inflammatory transcription factor 2). Thus, interactions between mycoplasmas and host cells are multifaceted and depend on the cellular context. In this review, we summarize the current information on the role of mycoplasmas in affecting the host’s intracellular signaling mediated by the interactions between transcriptional factors p53, Nrf2, and NF-κB. A better understanding of the mechanisms underlying pathologic processes associated with reprogramming eukaryotic cells that arise during the mycoplasma-host cell interaction should facilitate the development of new therapeutic approaches to treat oncogenic and inflammatory processes.
- Open Access
- 1 August 2019
- Published by Elsevier in Data in Brief
- Vol. 25, 104169
Data on proteomic profiling of cells and extracellular vesicles of the melittin-resistant Acholeplasma laidlawii strain
- 1 August 2019
- Published by Elsevier in Data in Brief
- Vol. 25, 104169
Open AccessData on proteomic profiling of cells and extracellular vesicles of the melittin-resistant Acholeplasma laidlawii strain
- 27 February 2019
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 14 (5) , 455-468
Omics of antimicrobials and antimicrobial resistance
Introduction: The development of new antimicrobials has become an urgent priority because of a global challenge emerging from the rise of antimicrobial resistant pathogens. Areas covered: In this review, the authors discuss the opportunities offered by modern omics approaches to address the challenge and the use of this approach in antimicrobial development. Specifically, the authors focus on the role of omics technologies and bioinformatics for the revelation of the effects of antimicrobials in a variety of microbial cellular processes, as well as the identification of potential cellular targets, the mechanisms of antimicrobial resistance, and the development of new antimicrobials. Expert opinion: Prevention of antimicrobial resistance does not only depend on rational drug design such as narrow-spectrum antimicrobials but on several factors. It is the opinion of the authors that the use of a multi-omics bioinformatics approach should become an integral part of antimicrobial drug discovery as well as in the prevention of antimicrobial resistance.
- 27 February 2019
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 14 (5) , 455-468
Omics of antimicrobials and antimicrobial resistance
Introduction: The development of new antimicrobials has become an urgent priority because of a global challenge emerging from the rise of antimicrobial resistant pathogens. Areas covered: In this review, the authors discuss the opportunities offered by modern omics approaches to address the challenge and the use of this approach in antimicrobial development. Specifically, the authors focus on the role of omics technologies and bioinformatics for the revelation of the effects of antimicrobials in a variety of microbial cellular processes, as well as the identification of potential cellular targets, the mechanisms of antimicrobial resistance, and the development of new antimicrobials. Expert opinion: Prevention of antimicrobial resistance does not only depend on rational drug design such as narrow-spectrum antimicrobials but on several factors. It is the opinion of the authors that the use of a multi-omics bioinformatics approach should become an integral part of antimicrobial drug discovery as well as in the prevention of antimicrobial resistance.
- 11 October 2018
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 24 (20) , 2236-2240
Mycoplasmas and Novel HO-1 Inducers: Recent Advances
Inflammation and the ways for its regulation: The development of an effective system for the treatment of inflammatory diseases requires comprehensive studies of the cellular signaling molecular networks comprising responses to various stressors, including pathogenic and non-pathogenic microorganisms. Significant attention on fundamental and applied research has recently focused on inducers of hemе oxygenase-1 (HO-1) and inhibitors of the expression of this enzyme, which regulates expression of this and other cytoprotective molecules and modulation of inflammation. Recent studies indicate that mycoplasmas (a major class of human pathogens) are capable of modulating inflammatory responses through the activation of the Nrf2 and the expression of HO-1. In vitro experiments demonstrate that the membrane lipoproteins (LAMPs), along with lipoprotein derivatives (lipopeptide MALP-2) in mycoplasmas cause a "cross-talk" between the pro- and anti-inflammatory signaling pathways. Importantly, lipopeptide/lipoprotein - induced expression of HO-1 tends to suppress inflammation. Conclusions: The study of the molecular network that causes the corresponding outcome can facilitate the development of new approaches for the treatment of inflammatory processes. The derivatives of LAMPs and MALP-2 and of their analogues may prove promising for the treatment of diseases associated with chronic inflammation.
- 11 October 2018
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 24 (20) , 2236-2240
Mycoplasmas and Novel HO-1 Inducers: Recent Advances
Inflammation and the ways for its regulation: The development of an effective system for the treatment of inflammatory diseases requires comprehensive studies of the cellular signaling molecular networks comprising responses to various stressors, including pathogenic and non-pathogenic microorganisms. Significant attention on fundamental and applied research has recently focused on inducers of hemе oxygenase-1 (HO-1) and inhibitors of the expression of this enzyme, which regulates expression of this and other cytoprotective molecules and modulation of inflammation. Recent studies indicate that mycoplasmas (a major class of human pathogens) are capable of modulating inflammatory responses through the activation of the Nrf2 and the expression of HO-1. In vitro experiments demonstrate that the membrane lipoproteins (LAMPs), along with lipoprotein derivatives (lipopeptide MALP-2) in mycoplasmas cause a "cross-talk" between the pro- and anti-inflammatory signaling pathways. Importantly, lipopeptide/lipoprotein - induced expression of HO-1 tends to suppress inflammation. Conclusions: The study of the molecular network that causes the corresponding outcome can facilitate the development of new approaches for the treatment of inflammatory processes. The derivatives of LAMPs and MALP-2 and of their analogues may prove promising for the treatment of diseases associated with chronic inflammation.
- 29 August 2018
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 13 (11) , 983-985
Antimicrobial drug discovery: lessons of history and future strategies
The discovery and development of the main classes of antimicrobials used in therapy of humans and animals has been recently overviewed [1]. The introduction of antimicrobials into clinical practice...
- 29 August 2018
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 13 (11) , 983-985
Antimicrobial drug discovery: lessons of history and future strategies
The discovery and development of the main classes of antimicrobials used in therapy of humans and animals has been recently overviewed [1]. The introduction of antimicrobials into clinical practice...
- 26 August 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (1) , 171-180
Effects of mycoplasma infection on the host organism response via p53/NF‐κB signaling
Mycoplasmas are bacteria lacking the cell wall, which is the major characteristic of this taxonomic class (Mollicutes). Among bacteria, mycoplasmas possess the smallest genome known for free‐living organisms. This feature limits the autonomy of bacteria and makes them increasingly susceptible to changes in the host organism. Many mycoplasmas themselves cause pathological changes in the host organism, often complicated by immune disorders. Infection with certain strains of mycoplasma results in the activation of the nuclear factor kappa‐light‐chain‐enhancer of activated B cells, which is the major mediator of the inflammatory response. Furthermore, mycoplasmas can inhibit p53‐mediated checkpoint control of cell cycle and apoptosis. Collectively, these properties indicate that mycoplasmas might act as cancer‐promoting factors. In this review, we summarize the information known to date on the role of mycoplasmas in the regulation of the host immune response and their functional interactions with p53.
- 26 August 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (1) , 171-180
Effects of mycoplasma infection on the host organism response via p53/NF‐κB signaling
Mycoplasmas are bacteria lacking the cell wall, which is the major characteristic of this taxonomic class (Mollicutes). Among bacteria, mycoplasmas possess the smallest genome known for free‐living organisms. This feature limits the autonomy of bacteria and makes them increasingly susceptible to changes in the host organism. Many mycoplasmas themselves cause pathological changes in the host organism, often complicated by immune disorders. Infection with certain strains of mycoplasma results in the activation of the nuclear factor kappa‐light‐chain‐enhancer of activated B cells, which is the major mediator of the inflammatory response. Furthermore, mycoplasmas can inhibit p53‐mediated checkpoint control of cell cycle and apoptosis. Collectively, these properties indicate that mycoplasmas might act as cancer‐promoting factors. In this review, we summarize the information known to date on the role of mycoplasmas in the regulation of the host immune response and their functional interactions with p53.
- 23 July 2018
- Published by Oxford University Press (OUP) in FEMS Microbiology Letters
- Vol. 365 (18)
Antimicrobial resistance in mollicutes: known and newly emerging mechanisms
This review is devoted to the mechanisms of antibiotic resistance in mollicutes (class Bacilli, subclass Mollicutes), the smallest self-replicating bacteria, that can cause diseases in plants, animals and humans, and also contaminate cell cultures and vaccine preparations. Research in this area has been mainly based on the ubiquitous mollicute and the main contaminant of cell cultures, Acholeplasma laidlawii. The omics technologies applied to this and other bacteria have yielded a complex picture of responses to antimicrobials, including their removal from the cell, the acquisition of antibiotic resistance genes and mutations that potentially allow global reprogramming of many cellular processes. This review provides a brief summary of well-known resistance mechanisms that have been demonstrated in several mollicutes species and, in more detail, novel mechanisms revealed in A. laidlawii, including the least explored vesicle-mediated transfer of short RNAs with a regulatory potency. We hope that this review highlights new avenues for further studies on antimicrobial resistance in these bacteria for both a basic science and an application perspective of infection control and management in clinical and research/production settings.
- 23 July 2018
- Published by Oxford University Press (OUP) in FEMS Microbiology Letters
- Vol. 365 (18)
Antimicrobial resistance in mollicutes: known and newly emerging mechanisms
This review is devoted to the mechanisms of antibiotic resistance in mollicutes (class Bacilli, subclass Mollicutes), the smallest self-replicating bacteria, that can cause diseases in plants, animals and humans, and also contaminate cell cultures and vaccine preparations. Research in this area has been mainly based on the ubiquitous mollicute and the main contaminant of cell cultures, Acholeplasma laidlawii. The omics technologies applied to this and other bacteria have yielded a complex picture of responses to antimicrobials, including their removal from the cell, the acquisition of antibiotic resistance genes and mutations that potentially allow global reprogramming of many cellular processes. This review provides a brief summary of well-known resistance mechanisms that have been demonstrated in several mollicutes species and, in more detail, novel mechanisms revealed in A. laidlawii, including the least explored vesicle-mediated transfer of short RNAs with a regulatory potency. We hope that this review highlights new avenues for further studies on antimicrobial resistance in these bacteria for both a basic science and an application perspective of infection control and management in clinical and research/production settings.
- Open Access
- 11 January 2018
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 6 (2) , e01446-17
Genome Sequences of Acholeplasma laidlawii Strains with Increased Resistance to Tetracycline and Melittin
Acholeplasma laidlawii is a well-suited model for studying the molecular basis for adapting mollicutes to environmental conditions. Here, we present the whole-genome sequences of two strains of A. laidlawii with increased resistance to tetracycline and melittin.
- 11 January 2018
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 6 (2) , e01446-17
Open AccessGenome Sequences of Acholeplasma laidlawii Strains with Increased Resistance to Tetracycline and Melittin
Acholeplasma laidlawii is a well-suited model for studying the molecular basis for adapting mollicutes to environmental conditions. Here, we present the whole-genome sequences of two strains of A. laidlawii with increased resistance to tetracycline and melittin.
- 1 January 2018
- Published by Pleiades Publishing Ltd in Citologiâ
- No. 9,p. 663-672
РОЛЬ МИКОПЛАЗМЕННОЙ ИНФЕКЦИИ В ХРОНИЧЕСКОМ ВОСПАЛЕНИИ И КАНЦЕРОГЕНЕЗЕ, "Цитология"
Многие виды микоплазм могут вызывать патологические изменения организма-хозяина, часто осложненные иммунными нарушениями. Воспалительные заболевания, связанные с микоплазменной инфекцией, известны как атипичная пневмония, мастит, уретрит, сальпингит, артрит и бронхолегочная дисплазия. Микоплазма может оказывать прямое влияние на метаболизм и физиологию клеток-хозяев, мешая процессу потребления питательных веществ, выделяя активные формы кислорода, которые вызывают генотоксический стресс. Ответ на повреждение ДНК обычно контролируется фактором транскрипции - белком р53, основным супрессором опухолей у человека, известным также как «хранитель генома». Однако в случае микоплазменной инфекции активность фактора р53 снижается. При этом происходит активация его физиологического антагониста, ядерного фактора NF-кБ, который является медиатором воспалительных реакций. Реакция на микоплазменную инфекцию у млекопитающих включает в себя несколько сигнальных систем, вызывающих активацию механизмов врожденного и приобретенного иммунитета и, следовательно, развитие как острых, так и хронических воспалительных процессов. Воспаление связано с действием иммунных медиаторов, которые высвобождаются эпителиальными клетками и лейкоцитами в ответ на инфекцию микоплазмой. Сигнальный каскад, вызванный распознаванием возбудителя, индуцирует активацию NF-кБ с последующей экспрессией провоспалительных цитокинов и хемокинов. Транскрипционный фактор NF-кБ обусловливает хроническое воспаление в месте инвазии патогена, которое на фоне подавления активности ядерного фактора р53 в конечном итоге формирует очаги, способствующие образованию опухоли.
- 1 January 2018
- Published by Pleiades Publishing Ltd in Citologiâ
- No. 9,p. 663-672
РОЛЬ МИКОПЛАЗМЕННОЙ ИНФЕКЦИИ В ХРОНИЧЕСКОМ ВОСПАЛЕНИИ И КАНЦЕРОГЕНЕЗЕ, "Цитология"
Многие виды микоплазм могут вызывать патологические изменения организма-хозяина, часто осложненные иммунными нарушениями. Воспалительные заболевания, связанные с микоплазменной инфекцией, известны как атипичная пневмония, мастит, уретрит, сальпингит, артрит и бронхолегочная дисплазия. Микоплазма может оказывать прямое влияние на метаболизм и физиологию клеток-хозяев, мешая процессу потребления питательных веществ, выделяя активные формы кислорода, которые вызывают генотоксический стресс. Ответ на повреждение ДНК обычно контролируется фактором транскрипции - белком р53, основным супрессором опухолей у человека, известным также как «хранитель генома». Однако в случае микоплазменной инфекции активность фактора р53 снижается. При этом происходит активация его физиологического антагониста, ядерного фактора NF-кБ, который является медиатором воспалительных реакций. Реакция на микоплазменную инфекцию у млекопитающих включает в себя несколько сигнальных систем, вызывающих активацию механизмов врожденного и приобретенного иммунитета и, следовательно, развитие как острых, так и хронических воспалительных процессов. Воспаление связано с действием иммунных медиаторов, которые высвобождаются эпителиальными клетками и лейкоцитами в ответ на инфекцию микоплазмой. Сигнальный каскад, вызванный распознаванием возбудителя, индуцирует активацию NF-кБ с последующей экспрессией провоспалительных цитокинов и хемокинов. Транскрипционный фактор NF-кБ обусловливает хроническое воспаление в месте инвазии патогена, которое на фоне подавления активности ядерного фактора р53 в конечном итоге формирует очаги, способствующие образованию опухоли.
- Open Access
- 2 November 2017
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 5 (44) , e01189-17
Genome Sequences of Acholeplasma laidlawii Strains Differing in Sensitivity to Ciprofloxacin
Acholeplasma laidlawii is a well-suited model for study of the molecular basis of the adaptation of mollicutes to environmental conditions. Here we present the whole-genome sequences of four strains of A. laidlawii with differential sensitivity to ciprofloxacin.
- 2 November 2017
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 5 (44) , e01189-17
Open AccessGenome Sequences of Acholeplasma laidlawii Strains Differing in Sensitivity to Ciprofloxacin
Acholeplasma laidlawii is a well-suited model for study of the molecular basis of the adaptation of mollicutes to environmental conditions. Here we present the whole-genome sequences of four strains of A. laidlawii with differential sensitivity to ciprofloxacin.